BACKGROUND/OBJECTIVES: Colonic fermentation of dietary fiber to short-chain fatty acids (SCFA) may protect against obesity and diabetes, but excess production of colonic SCFA has been implicated in the promotion of obesity. We aimed to compare the effects of two fermentable fibers on postprandial SCFA and second-meal glycemic response in healthy overweight or obese (OWO) vs lean (LN) participants. SUBJECTS/METHODS: Using a randomized crossover design, 13 OWO and 12 LN overnight fasted participants were studied for 6 h on three separate days after consuming 300 ml water containing 75 g glucose (GLU) as control or with 24 g inulin (IN) or 28 g resistant starch (RS). A standard lunch was served 4 h after the test drink. RESULTS: Within the entire group, compared with control, IN significantly increased serum SCFA (Po 0.001) but had no effect on free-fatty acids (FFA) or second-meal glucose and insulin responses. In contrast, RS had no significant effect on SCFA but reduced FFA rebound (P o 0.001) and second-meal glucose (P = 0.002) and insulin responses (P = 0.024). OWO had similar postprandial serum SCFA and glucose concentrations but significantly greater insulin and FFA than LN. However, the effects of IN and RS on SCFA, glucose, insulin and FFA responses were similar in LN and OWO. CONCLUSIONS: RS has favorable second-meal effects, likely related to changes in FFA rather than SCFA concentrations. However, a longer study may be needed to demonstrate an effect of RS on SCFA. We found no evidence that acute increases in SCFA after IN reduce glycemic responses in humans, and we were unable to detect a significant difference in SCFA responses between OWO vs LN subjects.
INTRODUCTION
High intake of dietary fiber is associated with reduced risk for type 2 diabetes mellitus (T2DM) and has been shown to improve glycemic control in T2DM. 1 These effects of fiber have been suggested to be due, at least in part, to its fermentation by colonic bacteria into the short-chain fatty acids (SCFA) acetate, propionate and butyrate, which are readily absorbed from the colonic lumen.
SCFA may improve glucose control by reducing serum FFA; high FFA concentrations induce peripheral and hepatic insulin resistance, 2, 3 and contribute to oxidative stress and thus deteriorate pancreatic β-cell function as well as insulin sensitivity. 4 Reductions of FFA have been demonstrated in animals after acetate injections 5, 6 and in humans after oral SCFA ingestion, 7 rectal SCFA infusion 8 and dietary fiber consumption. 9, 10 These effects were often, but not always, associated with reduced glycemic responses.
Different dietary fibers are fermented into different types and amounts of SCFA, 11, 12 therefore, may affect glycemic responses differently. Two fermentable dietary fibers of particular interest in this respect are resistant starch (RS) and inulin (IN). RS is an insoluble type of cereal fiber while IN is a soluble fiber that can be found in many types of plant foods. RS has been shown to increase insulin sensitivity in short-and long-term consumption studies; [13] [14] [15] [16] however, the mechanism is not clear. IN has been shown to improve glycemic control in animals; [17] [18] [19] [20] however, the results human studies have been equivocal. 10, 21, 22 The amount of SCFA produced in the colon also depends on the composition of the colonic microbiota. Obese mice harbor an increased abundance of Firmicutes and decreased Bacteroidetes than lean mice; 23 it has been suggested that such a microbiota produces SCFA (energy) more efficiently, and may therefore contribute to weight gain. 24 Human studies are limited but tend to show that fecal SCFA concentrations were significantly higher in obese than lean participants. [25] [26] [27] [28] Numerous studies have compared the fecal abundance of Firmicutes and Bacteroidetes in lean vs obese subjects but no consistent findings have emerged. [29] [30] [31] However, if obese humans produce SCFA more efficiently than lean humans, then excess SCFA production may contribute to weight gain and an increased risk for T2DM. On the other hand, excess SCFA production may lower FFA concentrations and improve glucose control, and therefore decrease risk for T2DM. Thus, our objective was to compare the effects of adding RS or IN to glucose tolerance test (75 g glucose) on acute postprandial responses of SCFA, glucose, insulin and FFA in overweight vs. lean participants. We hypothesized that, in overweight relative to lean 1 subjects, RS and IN would elicit higher postprandial SCFA responses and have less effect in reducing serum FFA and second-meal glucose and insulin responses.
MATERIALS AND METHODS Participants
Male and non-pregnant, non-lactating females aged 18-65 years with body mass index ⩾ 20 and ⩽ 35 kg/m 2 were recruited from a pool of participants previously involved in similar studies. Participants were excluded for any of the following reasons: presence of diabetes, cardiovascular, bowel, kidney or liver disease; use of medications that affect blood glucose or insulin sensitivity (such as diuretics); any use of antibiotics, laxatives, pre/probiotics or other drugs known to influence gastrointestinal function in the 3 months before the study; smoking; following any unusual dietary practices (such as weight loss diet, Atkins diet, vegan diet); abnormal plasma blood glucose (⩾7.0 mmol/l); or anemia. Eligible participants were then divided prospectively into two groups based on their body mass index: 12 participants in the LN group (body mass index o 25) and 13 participants in the OWO group (body mass index ⩾ 25). All tests were conducted at the Glycemic Index Laboratories, Toronto. Ethical approval for the study was obtained from the Research Ethics Board, University of Toronto. Participants gave written informed consent to participate in the study.
Phase 1
Participants completed questionnaires related to demographics, medical history, drug use, bowel habit and physical activity. 32, 33 They were given instructions on how to record their dietary intake and asked to keep a 3-day diet record. Participants were also given a fecal collection kit that consisted of the Fisher brand commode specimen collection system (Fisher Scientific, Ottawa, ON, Canada) and plastic bags. On the third day of the diet record or the day after, participants collected a fecal sample. The completed 3-day diet record and the plastic bag containing the fecal sample was immediately placed on dry ice, and brought to the lab within 24 h of being collected. The frozen fecal samples were stored at − 20°C until they were processed.
Phase 2
A week after completing phase 1, participants began phase 2; a crossover randomized controlled trial, in which participants came to the laboratory on three separate occasions, separated by a 1-week washout. On each study day, subjects arrived at 0800 hours after fasting for 12 h; after warming their forearms with a heating pad for 2-3 min, a cannula was inserted into a forearm vein and kept clear with periodic saline flushes. After a fasting blood sample was drawn, participants consumed a test drink within 5 min, and further blood samples were drawn at 0.5, 1, 1.5, 2, 3 and 4 h after the start of the test drink. Immediately after the 4-h blood sample, a standard lunch was provided. Participants ate the lunch within 15 min, and further blood samples were drawn at 4.5, 5, 5.5 and 6 h. Participants remained seated and awake for the duration of the study. Breath samples were collected at hourly intervals for 6 h for breath hydrogen and methane.
Test drinks
Each subject consumed all three treatments in random order. The sequence of the test meals were randomly assigned to the subjects by the study coordinator by using Random Integer Subject Generator (http:// www.random.org). The test drinks consisted of 75 g glucose (GLU) (Glucose; Grain Process Enterprises Ltd, Scarborough, ON, Canada) or 75 g glucose +24 g Oliggo-Fiber Instant Inulin (IN; 90% dietary fiber, 10% free fructose, glucose and saccharose; IN; Cargill Inc., Wayzata, MN, USA) or 75 g glucose +28 g RS (Nutriose FM06, Roquette, Lestrem, France; total fiber content of 85%; 24 g RS and 4.2 g rapidly digestible starch) dissolved in 300 ml water on the morning of the study. The IN dose of 24 g was based on a previous study from our lab 10 and the dose of 28 g RS was chosen so that the amount of fiber it contained equaled the dose of IN.
Standard lunch
The standard lunch consisted of a cheese and tomato sandwich, a drink of apple juice (200 ml), a bottle of water (500 ml) and two chocolate cookies (for more details see Supplementary Information).
Biochemistry
The fecal sample was weighed and homogenized in a 400 series masticator (IUL Instruments, S.A., Barcelona, Spain). Aliquots of feces were then transferred to individual vials for determination of pH and SCFA. Fecal pH was measured using a pH meter, and fecal SCFA were analyzed by gas chromatography as previously described. 34 DNA extraction and Ion Torrent V6 16 S-rRNA gene sequencing were performed as described elsewhere. 35 Compositional analysis of the data using Principle Component Biplots was done as described. 36 Blood for glucose, insulin, C-peptide and FFA was drawn into tubes containing spray-coated silica and a polymer gel for serum separation (BD Canada Inc., Oakville, ON, Canada). Blood for SCFA was drawn into the serum tube with no additive and an uncoated interior (BD Canada Inc., Oakville, ON, Canada). Serum glucose was measured by a glucose oxidase method (YSI 2300 STAT Plus; YSI Life Sciences Inc., Yellow Springs, OH, USA) (interassay coeffecient of variation o2%), insulin and C-peptide using the ELISA immunoassay (80-INSHU-E01.1 and 80-CPTHU-E01.1, E10; Alpco Diagnostic, Salem, NH, USA) (insulin: intra-and interassay coeffecient of variations o10 and o 17%, respectively; analytical sensitivity is 0.399 μlU/ ml. C-peptide: intra-and interassay coeffecient of variations o5 and o9%, respectively; analytical sensitivity 2.95 pmol/l). Serum FFA was measured using the enzymatic technique that used acyl-CoA oxidase (Wako NEFA-HR(2); Wako Chemicals USA, Inc., Richmond, VA, USA). All blood samples were allowed to clot at room temperature for 30 min, centrifuged at 3000 r.p.m. for 15 min at 4°C and the serum aliquoted and stored at − 70°C before analysis. Serum SCFA were measured by gas chromatography after microfiltration and vacuum distillation as previously described. 37 Breath samples of methane and hydrogen were measured by gas chromatography (Quintron Microlyzer, Model SC, Milwaukee, WI, USA) as previously described. 37 Power analysis-see Supplementary Information.
Statistical analysis
The primary results are reported as means ± s.e.m. For glucose, insulin and C-peptide, incremental areas under the curve (iAUC; subtracting area below the baseline) over 0-2 and 2-4 h were calculated using the fasting concentration as the baseline. For FFA, iAUC from the nadir to 4 h (iAUCmin4) was calculated using the minimum concentration achieved over the first 4 h as the baseline. For glucose, insulin, C-peptide and FFA, total areas under the curve (tAUC) were calculated over the 4-6 h periods using the trapezoidal method. For SCFA, tAUC were calculated over the 0-4 and 4-6 h periods, and iAUC from the nadir to 6 h (iAUCmin6) were calculated using the minimum concentration achieved over the first 4 h as the baseline. All AUCs were calculated using a computer spreadsheet (Microsoft Office Excel 2007).
To examine for the main effects of groups and treatments, and their interactions, the mixed-effects (random-effects) model was used to account for the within-participant correlation, which was introduced by the crossover design.
To investigate a possible relationship between serum FFA and SCFA and second-meal glucose responses, the difference in response between IN and Control and between RS and Control were calculated, and the differences in FFA and SCFA were correlated with the differences in glucose tAUC from 4 to 6 h. Two-group t-tests (two sided) were performed to analyze differences in baseline data between the groups. Differences were considered statistically significant if P ⩽ 0.05. Statistical analyses were conducted using IBM SPSS Statistics version 22 (SPSS Inc., Chicago, IL, USA) and Stata 13.0 (College Station, TX, USA).
RESULTS
Lean participants were significantly younger than OWO, but LN and OWO did not differ significantly with respect to sex and ethnicity ( Table 1) . Concentrations of fecal SCFA (Supplementary  Table S1 ) and fasting serum SCFA (Table 1) were not significantly different between the groups. However, after age adjustment, fecal propionate was significantly higher in the LN group compared with the OWO group (Supplementary Table S1 ). Fecal bacterial profiles at the level of phyla revealed no differences in the relative abundance of the Firmicutes and Bacteroidetes or in their ratio between the LN and the OWO group (Supplementary Figure S1 ). OWO had significantly higher fasting insulin, total and low-density lipoprotein cholesterol and triglycerides than LN, but similar glucose, aspartate transaminase, C-reactive protein and high-density lipoprotein cholesterol concentrations.
Lean had lower mean intakes of fat (g), protein (g), CHO (g) sugars (g) and total calories than the OWO group, but the differences were not significant (Supplementary Table S2 ).
Serum acetate, propionate and butyrate concentrations began to increase 2-4 h after IN and were significantly higher than GLU from 4 to 6 h ( Figure 1) ; thus, both the incremental AUC and the total AUC of all three SCFA after IN were significantly greater than those after GLU (Table 2) . By contrast, it took 5-6 h for mean serum SCFA concentrations after RS to begin to exceed those after GLU; by 6 h after RS the concentrations of all three SCFA were significantly greater than those after GLU by paired t-test when uncorrected for multiple comparisons (Figure 1 ), but the differences were small and there were no significant differences between RS and GLU in incremental or total AUC (Table 2 ). There were no significant differences in serum SCFA responses between LN and OWO subjects (Table 4) .
Breath hydrogen 2 h after IN was significantly greater than after GLU and increased rapidly to reach a peak concentration at 5 h, which was about 60ppm greater than that after GLU. Breath hydrogen after RS increased gradually to become significantly greater than GLU at 4 h, reaching a peak concentration at 5 h of approximately 10ppm (Supplementary Figure S3) . There was no difference in breath hydrogen responses between LN and OWO subjects (not shown). There were eight methane producers, and their mean breath methane concentration tended to fall throughout the day with no difference among treatments.
Glucose iAUC from 0 to 2 h was significantly greater after IN than GLU but the difference between RS and GLU not significant. However, after the standard lunch, tAUC 4-6 h was significantly less after RS than GLU but there was no difference between IN and GLU ( Figure 2 and Table 3 ). There were no significant differences in glycemic response between the LN and OWO groups (Table 4 ).
There was no difference among treatments in serum insulin or C-peptide responses between 0 and 2 h; however, the mean iAUC from 2 to 4 h was greater after RS compared with GLU, and the difference was significant for C-peptide. During the 4-6 h period, serum insulin and C-peptide responses after IN were similar to those after GLU, but, after RS, tAUC 4-6 h for serum insulin and Significant difference between resistant starch and glucose by related samples Wilcoxon signed rank test (Po0.05).
C-peptide were significantly less than those after GLU ( Figure 2 and Table 3 ). Serum insulin and C-peptide responses between 0-2 and 4-6 h were significantly greater in OWO compared with LN (Table 4 ) but the effects of IN and RS were similar in the two groups.
Serum FFA responses were similar after IN compared with GLU. However, over the 0-4 and 4-6 h periods, the total AUC for FFA was significantly less after RS than GLU, due to a significantly smaller rebound between the nadir and 4 h (Figure 2 and Table 3 ). FFA responses in LN did not differ significantly from those in OWO (Table 4) .
The interaction term was not significant for any of the outcomes (probably due to small sample size); therefore, the interaction term was dropped from the statistical model to save power for the main effects.
The changes in serum butyrate iAUC from minimum (nadir) to 6 h elicited by IN were negatively related to the changes in glucose tAUC at 4-6 h (P = 0.055) (Supplementary Table S3A ). The changes in serum FFA rise (minimum nadir to peak nadir) elicited by RS tend to negatively relate to glucose tAUC 4-6 h (P = 0.059) (Supplementary Table S3A ). The changes in acetate tAUC at 0-4 h elicited by IN were negatively correlated to the changes in FFA rise (P = 0.034; Supplementary Table S3B) .
DISCUSSION
It has been suggested, on the one hand, that excess production of colonic SCFA is a cause of obesity but on the other that colonic fermentation of dietary fiber improves insulin sensitivity, and therefore reduces the risk for T2DM. 14, 15, 38 Our results show no significant differences in postprandial SCFA responses between LN and OWO participants after acute fiber consumption. Moreover, unlike previous reports, 25, 26, 34 no significant differences in fecal SCFA concentrations between LN and OWO participants were ƒ Significant difference between resistant starch and glucose by related samples Wilcoxon signed rank test (P o0.05).
Short-chain fatty acids, glycemic response and adiposity S Rahat-Rozenbloom et al seen. This does not support the hypothesis that excess SCFA production is a cause of obesity. Our results also suggest that any effect of the colonic fermentation of dietary fiber on glycemic responses is not due to SCFA per se, since IN increased serum SCFA without reducing the second-meal glycemic response, whereas RS reduced the second-meal glycemic response without increasing serum SCFA. Although both IN and RS are fermentable, only IN elicited a significant increase in SCFA. The earlier elevation of acetate after IN compared with RS could reflect faster gastric emptying (which may also explain the increased glucose concentrations we saw after the IN breakfast), a more rapid transit of IN than RS through the small intestine, and more rapid and more proximal fermentation of IN than RS in the large intestine. 39 To our knowledge, no acute human studies have compared the fermentation of IN and RS. However, 12 h fermentation of fecal inocula from humans 40 showed that RS and IN produced similar amounts of total SCFA, with increased butyrate production from IN. Therefore, a study period longer than 6 h may be required to detect rises in serum SCFA after RS.
In this study, the lower glucose response after RS at 4-6 h compared with control, together with the reduced insulin and C-peptide responses, are consistent with other studies showing that RS treatment improves insulin sensitivity. 13, 15, 41, 42 This reduced glycemic response is likely not related to SCFA (as there was no significant increase in SCFA after RS), but rather to the reduced FFA rebound. The acute reduction in FFA could have been explained by the presence of a larger than expected amount of available, but slowly digested starch in the RS ingredient used, since both prolonged carbohydrate absorption 43 and an increase in the amount of carbohydrate absorbed 3 have been shown to reduce postprandial FFA rebound. The presence of enough additional available carbohydrate in the RS test meal compared with the control to reduce FFA at 3 and 4 h might be expected to increase serum glucose and insulin concentrations at these times. By contrast, we found that, compared with control, RS only elicited a small but significant increase in insulin at 3 h and a small nonsignificant increase in glucose at 3 h. However, these differences are quite consistent with those of a study showing that increasing the dose of glucose consumed from 75 to 100 g was associated with only a small increase in serum glucose (~0.4 mmol/l) at 3 h, a small reduction in glycose at 4 h, small increases in insulin (~50-70 pmol/L) at 3 and 4 h, and large reductions in FFA (40.1 mEq/l) at both 3 and 4 h. 44 The suggestion that the reduced FFA concentration accounted for the reduced second-meal glucose response is supported by the positive correlation between the FFA rise elicited by RS before lunch and glucose concentrations after lunch. Robertson et al. 14 demonstrated that supplementation of 30 g/day of RS for 4 weeks in healthy subjects significantly improved insulin sensitivity, reduced subcutaneous abdominal adipose tissue FFA (but not systemic FFA) and increased serum SCFA concentrations. However, in two other studies in healthy subjects, though a beneficial effect of RS on insulin sensitivity was seen, SCFA and FFA were either not measured 45 or showed no significant change. 15 In a 12-week study in T2DM humans, RS supplementation resulted in lower postprandial glucose concentrations and a reduction in fasting and postprandial FFA. However, no effects on insulin sensitivity or on serum SCFA concentrations were seen. 41 Thus, more human studies are needed to understand how RS reduce glycemic responses
The inability of IN to elicit a significant reduction in postprandial FFA rebound, despite a large increase in serum SCFA concentrations, was unexpected and not consistent with the results of several previous studies from our laboratory. 10, 37 The increased glucose response before lunch was also unexpected and inconsistent with our previous studies that showed that the glycemic response after adding 24 g IN to either high-fructose corn syrup 10 or to 75 g glucose 46 was virtually identical to that after the control. The inverse relation between butyrate (min-6 h) and glycemic responses at 4-6 h may show that butyrate may has a role in reducing glucose, 47 though its elevation might not be consistent and high enough to significantly reduce blood glucose. Though animal studies have shown a positive effect of the IN-type fructans on glucose control, [17] [18] [19] a systematic review in humans did not find a conclusive result, 21 possibly due to the differences among studies in fructan types, doses, durations of studies, health status of the participants and analytical methods. Further investigations are needed in order to determine whether IN has any effect on glycemic control. Surprisingly, we found no significant differences in serum SCFA responses between LN and OWO groups. However, this do not rule out increased colonic SCFA production in OWO compared with LN participants, since if this was also accompanied by increased hepatic and peripheral SCFA clearance, postprandial serum SCFA responses could be similar in the two groups. Moreover, a modest difference in SCFA responses between OWO and LN could have been missed, as about 85 subjects per group would be required to detect, with statistical significance, the difference we actually observed. With our current sample size, and with 80% power, a significant difference would have been detected only if the OWO group had produced almost twice the amount of acetate after IN than the amount the LN group produced. However, the lack of differences between our groups in fecal SCFA concentrations (as opposed to previous human studies [25] [26] [27] ), in fecal bacterial phyla, and in habitual dietary intakes, may suggest that the group of OWO subjects we studied did not produce more SCFA than the LN subjects. Whether the similar fecal and serum SCFA responses in our groups were due to their similar relative abundance of Firmicutes and Bacteroides, due to other factors that were not explored in our study (that is, genetic variations 48 ), or due to a small sample size, should be further explored.
It is concluded that IN and RS differ in their acute postprandial effects: IN is rapidly fermented in the colon eliciting prompt and large increases in breath hydrogen and serum SCFA concentrations, whereas RS is more slowly fermented with much smaller increases in breath hydrogen and serum SCFA for 6 h after consumption. The results provide no evidence that acute elevations in SCFA per se influence glucose metabolism. In addition, the results do not support the hypothesis that overweight/obesity is associated with increased colonic SCFA production. However, a larger sample size would be needed to rule out a modest increase in SCFA production in obesity.
